|
TW200801012A
(en)
*
|
2006-04-26 |
2008-01-01 |
Piramed Ltd |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
WO2009143389A1
(en)
|
2008-05-21 |
2009-11-26 |
Ariad Pharmaceuticals, Inc. |
Phosphorous derivatives as kinase inhibitors
|
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
WO2011060321A1
(en)
|
2009-11-16 |
2011-05-19 |
Chdi, Inc. |
Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
|
|
EP2519664A4
(en)
|
2009-12-30 |
2014-03-12 |
Avila Therapeutics Inc |
LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
|
|
EP2678018A4
(en)
|
2011-02-23 |
2015-09-30 |
Intellikine Llc |
COMBINATION OF CHINESE HEMMER AND USES THEREOF
|
|
JP2014511395A
(ja)
*
|
2011-03-09 |
2014-05-15 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
Ｐｉ３キナーゼインヒビターおよびその使用
|
|
CN103501612B
(zh)
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
|
|
WO2012154608A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
|
WO2012154610A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive pi3k kinase inhibitors and uses thereof
|
|
US8889716B2
(en)
|
2011-05-10 |
2014-11-18 |
Chdi Foundation, Inc. |
Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
|
|
EP2731612A4
(en)
|
2011-07-13 |
2015-04-08 |
Pharmacyclics Inc |
BRUTON TYROSINE KINASE HEMMER
|
|
TWI547493B
(zh)
|
2011-09-27 |
2016-09-01 |
諾華公司 |
作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
US9260441B2
(en)
|
2012-03-28 |
2016-02-16 |
Intervet Inc. |
Heteroaryl compounds with cyclic bridging unit
|
|
CN104379563B
(zh)
*
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
WO2013154778A1
(en)
*
|
2012-04-11 |
2013-10-17 |
Dana-Farber Cancer Institute, Inc. |
Host targeted inhibitors of dengue virus and other viruses
|
|
DK2841075T3
(da)
|
2012-04-26 |
2020-06-22 |
Massachusetts Gen Hospital |
Midler og fremgangsmåder til behandling og forebyggelse af seboroisk keratose
|
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
|
|
WO2013173454A1
(en)
*
|
2012-05-15 |
2013-11-21 |
New York University |
Phosphatidylinositol-3-kinase c2 beta modulators and methods of use thereof
|
|
WO2014012093A1
(en)
*
|
2012-07-13 |
2014-01-16 |
Wake Forest University Health Sciences |
Prostate cancer targeted prodrugs and methods of use thereof
|
|
WO2014022569A1
(en)
*
|
2012-08-03 |
2014-02-06 |
Principia Biopharma Inc. |
Treatment of dry eye
|
|
MX363822B
(es)
|
2012-08-21 |
2019-04-04 |
Opko Pharmaceuticals Llc |
Formulaciones de liposomas.
|
|
US11458199B2
(en)
|
2012-08-21 |
2022-10-04 |
Opko Pharmaceuticals, Llc |
Liposome formulations
|
|
HK1211942A1
(en)
|
2012-09-10 |
2016-06-03 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
EP2935246B1
(en)
|
2012-12-21 |
2018-07-25 |
Gilead Calistoga LLC |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
|
CA2895782C
(en)
|
2012-12-21 |
2017-08-22 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
|
ES2831625T3
(es)
*
|
2013-02-20 |
2021-06-09 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos
|
|
WO2014141104A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
JP6433974B2
(ja)
|
2013-03-14 |
2018-12-05 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
|
|
EP2968340A4
(en)
*
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
MX364438B
(es)
*
|
2013-03-15 |
2019-04-26 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
|
JP6378918B2
(ja)
*
|
2013-04-03 |
2018-08-22 |
株式会社ヤクルト本社 |
チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
MA42164B1
(fr)
|
2013-05-01 |
2019-12-31 |
Hoffmann La Roche |
Composes biheteroaryle et leurs utilisations
|
|
US10508309B2
(en)
*
|
2013-05-17 |
2019-12-17 |
The General Hospital Corporation |
Methods for detecting and treating variants of seborrheic keratoses
|
|
PL3008053T3
(pl)
|
2013-06-14 |
2018-08-31 |
Gilead Calistoga Llc |
Inhibitory 3-kinazy fosfatydyloinozytolu
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
CA2925124A1
(en)
|
2013-09-30 |
2015-04-02 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
AU2014334554B2
(en)
|
2013-10-14 |
2018-12-06 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
|
BR112016008378B1
(pt)
|
2013-10-14 |
2022-11-08 |
Eisai R&D Management Co., Ltd |
Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos
|
|
WO2015058126A1
(en)
*
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
US10047084B2
(en)
|
2013-11-20 |
2018-08-14 |
Beijing Forelandpharma Co. Ltd. |
Imidazolone derivatives, pharmaceutical compositions and uses thereof
|
|
AU2014360743C1
(en)
|
2013-12-02 |
2021-01-28 |
Chemocentryx, Inc. |
CCR6 compounds
|
|
MX372673B
(es)
|
2014-02-21 |
2020-03-25 |
Principia Biopharma Inc |
Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
PT3233103T
(pt)
|
2014-12-18 |
2021-01-18 |
Principia Biopharma Inc |
Tratamento de pênfigo
|
|
PL3236983T3
(pl)
*
|
2014-12-24 |
2019-10-31 |
Kither Biotech S R L |
Nowy peptydowy inhibitor PI3K gamma do leczenia chorób układu oddechowego
|
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
WO2016172952A1
(zh)
*
|
2015-04-30 |
2016-11-03 |
江苏挪贝肽医药科技有限公司 |
PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
|
|
MX2017014776A
(es)
|
2015-05-20 |
2018-02-15 |
Novartis Ag |
Combinacion farmaceutica de everolimus con dactolisib.
|
|
MA42242A
(fr)
|
2015-06-24 |
2018-05-02 |
Principia Biopharma Inc |
Inhibiteurs de la tyrosine kinase
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3364977A4
(en)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
PROCESS FOR SCREENING INHIBITORS OF RAS
|
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
RU2617409C1
(ru)
*
|
2015-12-24 |
2017-04-25 |
Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) |
Амиды акриловой и метакриловой кислот с n-алкилпиперазино-пиперидинами и способ их получения
|
|
RU2617694C1
(ru)
*
|
2015-12-24 |
2017-04-26 |
Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) |
Амиды акриловой и метакриловой кислот с олигопиперидинами и способ их получения
|
|
GB201602527D0
(en)
*
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
CN109311858B
(zh)
|
2016-05-26 |
2021-12-03 |
里科瑞尔姆Ip控股有限责任公司 |
Egfr抑制剂化合物
|
|
EA201892836A1
(ru)
|
2016-06-29 |
2019-07-31 |
Принсипиа Биофарма Инк. |
Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
|
|
WO2018002958A1
(en)
|
2016-06-30 |
2018-01-04 |
Sun Pharma Advanced Research Company Limited |
Novel hydrazide containing compounds as btk inhibitors
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
|
BR112019010470A2
(pt)
|
2016-11-23 |
2019-09-10 |
Novartis Ag |
métodos de realce de resposta imune com everolimo, dactolisib ou ambos
|
|
CN106755343A
(zh)
*
|
2016-12-01 |
2017-05-31 |
北京致成生物医学科技有限公司 |
胰腺癌预后诊断分子标记物
|
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
US10858351B2
(en)
*
|
2017-04-26 |
2020-12-08 |
Alberta Research Chemicals Inc. |
Substituted tetrahydropyridine derivatives as IDO-1 inhibitors and uses thereof
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
|
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
|
AU2019247498A1
(en)
|
2018-04-05 |
2020-11-26 |
Sumitomo Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
|
MX2020010577A
(es)
|
2018-04-10 |
2021-03-02 |
Neuropore Therapies Inc |
Derivados de morfolina como inhibidores de vps34.
|
|
ES3032793T3
(en)
|
2018-04-10 |
2025-07-24 |
Neuropore Therapies Inc |
Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
BR112021001709A2
(pt)
*
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
KR102328682B1
(ko)
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
EP3849545A1
(en)
*
|
2018-09-10 |
2021-07-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of neurofibromatosis
|
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
JP2022515197A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
|
|
MX2022003217A
(es)
|
2019-09-19 |
2022-06-29 |
Totus Medicines Inc |
Conjugados terapeuticos.
|
|
MX2022004427A
(es)
|
2019-10-14 |
2022-07-12 |
Principia Biopharma Inc |
Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
|
|
CN114793434A
(zh)
|
2019-10-18 |
2022-07-26 |
加利福尼亚大学董事会 |
作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物
|
|
AU2021206240A1
(en)
*
|
2020-01-10 |
2022-08-25 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
MX2022009009A
(es)
|
2020-01-22 |
2022-08-15 |
Principia Biopharma Inc |
Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
|
|
TWI883391B
(zh)
|
2020-02-18 |
2025-05-11 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
TWI775313B
(zh)
|
2020-02-18 |
2022-08-21 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
CN115135383B
(zh)
|
2020-02-18 |
2024-06-11 |
吉利德科学公司 |
抗病毒化合物
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
US20230201202A1
(en)
*
|
2020-05-27 |
2023-06-29 |
Duke University |
Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
CN113045582B
(zh)
*
|
2021-02-05 |
2022-12-23 |
中国药科大学 |
Parp-1/pi3k双靶点抑制剂或其药学上可接受的盐及其制备方法与用途
|
|
WO2022198024A1
(en)
*
|
2021-03-18 |
2022-09-22 |
Totus Medicines Inc. |
Therapeutic conjugates
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
US20240208957A1
(en)
*
|
2021-04-09 |
2024-06-27 |
Universität Basel |
Triazine derivative as reversible and irreversible covalent inhibitors of pi3k
|
|
CN117396470A
(zh)
*
|
2021-04-09 |
2024-01-12 |
巴塞尔大学 |
作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物
|
|
JP7688152B2
(ja)
|
2021-04-16 |
2025-06-03 |
ギリアード サイエンシーズ， インコーポレイテッド |
アミドを使用してカルバヌクレオシドを調製する方法
|
|
AU2022306671A1
(en)
|
2021-07-07 |
2024-01-25 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
TW202321191A
(zh)
*
|
2021-07-29 |
2023-06-01 |
美商賽迪拉治療股份有限公司 |
Ｔｅａｄ抑制劑及其用途
|
|
KR20240049311A
(ko)
|
2021-08-18 |
2024-04-16 |
길리애드 사이언시즈, 인코포레이티드 |
인지질 화합물 및 이의 제조 및 사용 방법
|
|
JP2024534187A
(ja)
|
2021-08-31 |
2024-09-18 |
インサイト・コーポレイション |
Ｋｒａｓの阻害剤としてのナフチリジン化合物
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
CN113754680B
(zh)
*
|
2021-09-28 |
2022-07-22 |
云白药征武科技(上海)有限公司 |
一种α氟代酰基哌嗪衍生物及其制备和应用
|
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
PE20242113A1
(es)
|
2021-10-14 |
2024-10-28 |
Incyte Corp |
Compuestos de quinolina como inhibidores de kras
|
|
WO2024182447A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Vividion Therapeutics, Inc. |
Compounds and methods for modulating ras-pi3k
|
|
WO2025188658A1
(en)
*
|
2024-03-06 |
2025-09-12 |
Alterome Therapeutics, Inc. |
Akt1 modulators
|